Contributions to Hypertension Public Policy and Clinical Practice: A Review of Recent Reports.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Home blood pressure control status in 2017-2018 for hypertension specialist centers in Asia: Results of the Asia BP@Home study.Journal of clinical hypertension (Greenwich, Conn.) · 2018
   Trial
2. Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research.Stroke · 2018
   Review
3. The HOPE Asia Network for "zero" cardiovascular events in Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2018
   Article
4. Prevalence and correlates of hypertension in a semi-rural population of Southern India.Journal of human hypertension · 2017
   Article
5. Experts Provide a Glimpse of the New Post-SPRINT Era of Hypertension.P & T : a peer-reviewed journal for formulary management · 2017
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as